...
首页> 外文期刊>Yonsei Medical Journal >Can Western Based Online Prostate Cancer Risk Calculators Be Used to Predict Prostate Cancer after Prostate Biopsy for the Korean Population?
【24h】

Can Western Based Online Prostate Cancer Risk Calculators Be Used to Predict Prostate Cancer after Prostate Biopsy for the Korean Population?

机译:在韩国人群进行前列腺穿刺活检后,可以使用基于西方的在线前列腺癌风险计算器来预测前列腺癌吗?

获取原文
           

摘要

Purpose To access the predictive value of the European Randomized Screening of Prostate Cancer Risk Calculator (ERSPC-RC) and the Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) in the Korean population. Materials and Methods We retrospectively analyzed the data of 517 men who underwent transrectal ultrasound guided prostate biopsy between January 2008 and November 2010. Simple and multiple logistic regression analysis were performed to compare the result of prostate biopsy. Area under the receiver operating characteristics curves (AUC-ROC) and calibration plots were prepared for further analysis to compare the risk calculators and other clinical variables. Results Prostate cancer was diagnosed in 125 (24.1%) men. For prostate cancer prediction, the area under curve (AUC) of the ERSPC-RC was 77.4%. This result was significantly greater than the AUCs of the PCPT-RC and the prostate-specific antigen (PSA) (64.5% and 64.1%, respectively, p Conclusion The ERSPC-RC was better than PCPT-RC and PSA in predicting prostate cancer risk in the present study. However, the difference in performance between the ERSPC-RC and PSAD was not significant. Therefore, the Western based prostate cancer risk calculators are not useful for urologists in predicting prostate cancer in the Korean population.
机译:目的访问欧洲人群对韩国人群进行的前列腺癌风险计算器(ERSPC-RC)和前列腺癌预防试验风险计算器(PCPT-RC)的预测价值。资料与方法我们回顾性分析了2008年1月至2010年11月经直肠超声引导下穿刺活检的517例男性的数据。进行了简单和多因素Logistic回归分析,比较了前列腺穿刺活检的结果。准备好接收器工作特性曲线(AUC-ROC)下的面积和校准图以进行进一步分析,以比较风险计算器和其他临床变量。结果在125名(24.1%)男性中诊断出前列腺癌。对于前列腺癌的预测,ERSPC-RC的曲线下面积(AUC)为77.4%。该结果显着高于PCPT-RC和前列腺特异性抗原(PSA)的AUC(分别为64.5%和64.1%,p)结论ERSPC-RC在预测前列腺癌风险方面优于PCPT-RC和PSA。在本研究中,然而,ERSPC-RC和PSAD的性能差异不明显,因此,基于西方的前列腺癌风险计算器对泌尿科医生预测韩国人群的前列腺癌没有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号